Weight Loss Plateau After GLP-1: How a Las Vegas & Henderson Physician Can Help
You started a GLP-1 medication. The first few months went well — measurable weight loss, better appetite control, real momentum. And then, suddenly, the scale stops moving. This is one of the most common reasons adults in Las Vegas and Henderson search for a weight loss plateau after GLP-1 physician. This guide explains why GLP-1 plateaus happen, what a physician-led evaluation looks for, and when to consider a next step.
Why GLP-1 plateaus happen
A GLP-1 plateau is not a personal failure. It is a predictable biological response. As you lose weight, your body activates compensatory mechanisms: leptin drops, hunger signals return, resting metabolic rate declines, and the same dose that worked at month two stops producing the same trajectory at month six.
This is why "just increase the dose" is rarely the right first answer. A physician-led evaluation looks at the whole picture — labs, sleep, training, hormones, medications, and the underlying drivers of the plateau — before deciding on a next step.
How a physician-led Las Vegas or Henderson clinic evaluates a plateau
At LiveNow Longevity, our weight management program is led by Dr. Charles Kamen, MD. A plateau evaluation includes a clinical consultation, a review of your GLP-1 history, a comprehensive lab panel, and a goal-based discussion.
Labs typically include a full metabolic panel, lipid panel, hormone panel, and markers relevant to weight-loss resistance. The goal is not just to push past the plateau — it is to understand why your body is responding this way and what the safest, most effective next step is.
Treatment options when a plateau is real
A plateau protocol may include peptide therapy, NAD+, prescription weight-loss medications, hormone optimization, IV therapy, and targeted lifestyle changes — but only after evaluation and only when medically appropriate.
Retatrutide and other triple-hormone peptides may be considered as part of a weight management protocol when medically appropriate and clinically indicated. Inclusion of any peptide in your plan depends on a complete medical evaluation, your health history, current medications, lab work, and goals. We do not promise specific results.
What a plateau evaluation at LiveNow includes
- Clinical consultation with Dr. Charles Kamen, MD — board-certified neurologist
- Comprehensive lab panel to identify metabolic and hormonal drivers
- Honest recommendation on whether dose escalation, peptide switching, or adjunct therapy is appropriate
- Peptides and medications sourced from licensed US 503A/503B compounding pharmacies
- Ongoing physician supervision — not a telehealth auto-renewal
Frequently asked questions
How long does a GLP-1 plateau typically last?
Plateaus can occur at any point but are most common 4 to 6 months in. The duration depends on dose, adherence, baseline metabolism, sleep, training, and underlying hormonal drivers. A physician-led evaluation can identify which factors are most likely contributing.
Is it safe to increase my GLP-1 dose on my own?
No. Dose escalation should only be done under physician supervision with appropriate lab work. The right answer is not always "more of the same medication" — sometimes it is a different medication, an adjunct peptide, or a metabolic workup.
Do you see Henderson patients for weight loss plateau?
Yes. Many Henderson, Green Valley, Anthem, and Seven Hills patients come to our <a href="/peptide-clinic-henderson">Henderson peptide clinic</a> after hitting a plateau. See our <a href="/peptide-clinic-las-vegas">Las Vegas weight management page</a> for full details.
A GLP-1 plateau is a real clinical event, not a personal failure, and it deserves a real clinical answer. If you have hit a wall on a GLP-1 medication and want a physician-led next step, the fastest way forward is a complete medical evaluation. Schedule your $88 evaluation at our Las Vegas peptide clinic or our Henderson peptide clinic and bring your current medication list and any recent labs.
References
- Hall KD, et al. Lancet. 2024;403(10435):1473-1482. (Metabolic adaptation)
- Jastreboff AM, et al. NEJM. 2023;389(6):514-525.
- Müller TD, et al. Nat Rev Endocrinol. 2024;20(7):399-414.